Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
The chart shows the growth of an initial investment of $10,000 in Clover Health Investments, Corp, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Clover Health Investments, Corp (CLOV) has returned -27.73% so far this year and -43.61% over the past 12 months. Looking at the last ten years, CLOV has achieved an annualized return of -19.63%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
CLOV
1M-20.37%
6M-34.10%
YTD-27.73%
1Y-43.61%
5Y-26.61%
10Y-19.63%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Clover Health Investments, Corp (CLOV) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-5.88%
-5.86%
-14.15%
-1.15%
2025
38.49%
-5.02%
-9.34%
-4.23%
-7.65%
-11.15%
4.33%
-9.34%
18.15%
16.50%
-29.46%
-4.08%
2024
0.86%
-11.12%
-8.74%
-21.25%
73.23%
6.96%
56.56%
38.42%
8.88%
47.14%
-16.14%
-7.89%
2023
40.80%
-1.49%
-35.48%
-12.59%
12.92%
7.36%
43.14%
2.34%
-19.40%
-11.73%
-2.02%
3.10%
2022
-31.75%
3.42%
29.09%
-24.23%
-19.85%
30.84%
-5.43%
-33.33%
-7.06%
-19.63%
-28.50%
2021
-8.82%
-33.47%
-24.17%
29.10%
-25.02%
74.12%
-38.91%
5.49%
-13.06%
-0.13%
-34.04%
-25.00%
Performance Indicators
The charts below present risk-adjusted performance metrics for Clover Health Investments, Corp (CLOV) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CLOV compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Clover Health Investments, Corp volatility is 1.73%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2023
2022
2021
Liabilities And Equity (USD)
541.01M
570.67M
808.62M
950.80M
Temporary Equity Attributable To Parent (USD)
-
-
-
-
Temporary Equity (USD)
-
-
-
-
Equity Attributable To Parent (USD)
308.70M
286.39M
347.74M
535.41M
Equity Attributable To Noncontrolling Interest (USD)
The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.
Benzinga•Equity Insider
AI Insight
Counterpart Health subsidiary demonstrated AI platform effectiveness with 22% reduction in flu-related acute care encounters in COPD patients and 18% in CHF patients, supporting expansion of AI-enabled clinical workflows beyond internal membership.
The global insurtech market is projected to grow from $14 billion in 2026 to $638 billion by 2035, at a CAGR of 41.45%. Growth is driven by AI, blockchain, cloud computing, and machine learning technologies, with collaborations between traditional insurers and startups accelerating innovation. North America leads the market, while Asia is expected to grow faster. Health insurance, managed services, and cloud computing segments dominate, with healthcare sector showing highest future growth potential.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Listed as a leading company in the competitive landscape of the rapidly growing insurtech market with projected 41.45% CAGR through 2035, indicating strong industry tailwinds and market opportunity.
Fiserv reported disappointing Q3 earnings, with revenue and earnings missing analyst expectations, leading to a 30% stock collapse and a comprehensive strategic restructuring including leadership changes and reduced financial guidance.
Investing.com•Timothy Fries
AI Insight
Mentioned as part of Fiserv's strategic small business platform development
Chamath Palihapitiya launched a new SPAC called American Exceptionalism Acquisition Corp, but is advising retail investors to avoid it due to high risk and complex investment structure. He emphasized that 98.7% of the SPAC was allocated to institutional investors.
The global AI in healthcare market is projected to reach nearly $700 billion by 2034, growing at 38.5% annually. Companies are developing advanced AI diagnostic technologies targeting areas like diabetic retinopathy, cardiac screening, and chronic disease management, with increasing FDA approvals and commercial potential.
Benzinga•Prnewswire
AI Insight
Released clinical data showing AI-powered technology improves COPD patient outcomes with reduced hospitalizations
The healthcare AI market is projected to surge at a 30% compound annual growth rate through 2030, driven by increased investment across hospitals, insurers, and pharma. Companies like Avant Technologies, Amesite, Oracle, Clover Health, and Alphabet are making advancements in AI-powered healthcare solutions.
Benzinga•Prnewswire
AI Insight
The company's Counterpart Assistant platform is partnering with Alphabet's Google Cloud to enhance clinical workflows, reduce administrative burdens, and support better outcomes in value-based care.
The healthcare AI market is projected to surge at a 30% compound annual growth rate through 2030, driven by new investments across hospitals, insurers, and pharma. Companies like Avant Technologies, Amesite, Oracle, Clover Health, and Alphabet are making advancements in AI-powered healthcare solutions.
Benzinga•Prnewswire
AI Insight
Clover Health's Counterpart Assistant platform is partnering with Alphabet's Google Cloud to integrate AI-powered search capabilities, aiming to streamline clinical workflows and reduce administrative burdens for physicians.
Clover Health announced that Lee A. Shapiro will not stand for re-election to the Board of Directors, and Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee.
GlobeNewswire Inc.•
AI Insight
The article highlights positive changes in Clover Health's Board of Directors, with Thomas L. Tran taking on expanded leadership roles, indicating the company's commitment to strong governance and oversight.
Hindenburg Research, a notable short-seller, has targeted several high-profile stocks with scathing reports, leading to significant stock price declines. The article examines the impact of Hindenburg's reports on Clover Health, DraftKings, and Block, and discusses the potential risks and biases associated with short-seller reports.
The Motley Fool•The Motley Fool
AI Insight
The article states that Clover Health's stock has crashed by approximately 80% since Hindenburg's short-seller report, and the company continues to struggle with profitability and a thin gross profit margin.
FRANKLIN, Tenn., June 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).
GlobeNewswire Inc.•Clover Health Investments, Corp.
